Evidence map›Paper›PMID 31024328›Full record

ArticleFrontiers in physiology2019

Optogenetic Monitoring of the Glutathione Redox State in Engineered Human Myocardium.

Irina Trautsch, Eriona Heta, Poh Loong Soong, Elif Levent, Viacheslav O Nikolaev, Ivan Bogeski, Dörthe M Katschinski, Manuel Mayr, Wolfram-Hubertus Zimmermann

Open access · goldAbstract read
In one paragraph

Article in Frontiers in physiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Cardiac optogenetics: a decade of enlightenment.Nature reviews. Cardiology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Irina TrautschInstitute of Pharmacology & Toxicology, University Medical Center Göttingen, Göttingen, Germany.
Eriona HetaInstitute of Pharmacology & Toxicology, University Medical Center Göttingen, Göttingen, Germany.
Poh Loong SoongInstitute of Pharmacology & Toxicology, University Medical Center Göttingen, Göttingen, Germany.
Elif LeventInstitute of Pharmacology & Toxicology, University Medical Center Göttingen, Göttingen, Germany.
Viacheslav O NikolaevInstitute for Experimental Cardiovascular Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Ivan BogeskiDZHK (German Center for Cardiovascular Research), Partner Site Göttingen, Göttingen, Germany.
Dörthe M KatschinskiDZHK (German Center for Cardiovascular Research), Partner Site Göttingen, Göttingen, Germany.
Manuel MayrKing's British Heart Foundation Centre, King's College London, London, United Kingdom.
Wolfram-Hubertus ZimmermannInstitute of Pharmacology & Toxicology, University Medical Center Göttingen, Göttingen, Germany.
University of Göttingen · DEGerman Centre for Cardiovascular Research · DEKing's College London · GBUniversität Hamburg · DEUniversitätsmedizin Göttingen · DE

Funding

British Heart Foundation CH/16/3/32406British Heart Foundation RG/16/14/32397British Heart Foundation SP/17/10/33219
6 · The paper itself

Abstract

Redox signaling affects all aspects of cardiac function and homeostasis. With the development of genetically encoded fluorescent redox sensors, novel tools for the optogenetic investigation of redox signaling have emerged. Here, we sought to develop a human heart muscle model for in-tissue imaging of redox alterations. For this, we made use of (1) the genetically-encoded Grx1-roGFP2 sensor, which reports changes in cellular glutathione redox status (GSH/GSSG), (2) human embryonic stem cells (HES2), and (3) the engineered heart muscle (EHM) technology. We first generated HES2 lines expressing Grx1-roGFP2 in cytosol or mitochondria compartments by TALEN-guided genomic integration. Grx1-roGFP2 sensor localization and function was verified by fluorescence imaging. Grx1-roGFP2 HES2 were then subjected to directed differentiation to obtain high purity cardiomyocyte populations. Despite being able to report glutathione redox potential from cytosol and mitochondria, we observed dysfunctional sarcomerogenesis in Grx1-roGFP2 expressing cardiomyocytes. Conversely, lentiviral transduction of Grx1-roGFP2 in already differentiated HES2-cardiomyocytes and human foreskin fibroblast was possible, without compromising cell function as determined in EHM from defined Grx1-roGFP2-expressing cardiomyocyte and fibroblast populations. Finally, cell-type specific GSH/GSSG imaging was demonstrated in EHM. Collectively, our observations suggests a crucial role for redox signaling in cardiomyocyte differentiation and provide a solution as to how this apparent limitation can be overcome to enable cell-type specific GSH/GSSG imaging in a human heart muscle context.

Indexed as

cardiomyocytesengineered human myocardiumfibroblastsGSHoptogeneticsredox-reportersroGFPstem cells

Identifiers

PMID31024328
PMCPMC6460052
OpenAlexW2933960061

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.